Delcath Systems (NASDAQ:DCTH) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Delcath Systems (NASDAQ:DCTH) in a report issued on Monday,Benzinga reports. They currently have a $22.00 price objective on the stock. HC Wainwright also issued estimates for Delcath Systems’ Q4 2024 earnings at ($0.10) EPS, FY2024 earnings at ($0.90) EPS, Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($0.87) EPS, FY2026 earnings at ($0.23) EPS, FY2027 earnings at $0.76 EPS and FY2028 earnings at $1.46 EPS.

Several other equities research analysts have also issued reports on DCTH. Stephens reiterated a “buy” rating on shares of Delcath Systems in a report on Friday, October 18th. StockNews.com raised shares of Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $21.00 price target on shares of Delcath Systems in a report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Delcath Systems has an average rating of “Moderate Buy” and a consensus target price of $21.50.

Delcath Systems Trading Down 1.9 %

Shares of NASDAQ:DCTH opened at $9.23 on Monday. The business has a fifty day simple moving average of $9.71 and a 200 day simple moving average of $8.43. Delcath Systems has a 1 year low of $2.30 and a 1 year high of $12.88. The firm has a market cap of $295.08 million, a price-to-earnings ratio of -6.97 and a beta of 0.75.

Institutional Investors Weigh In On Delcath Systems

A number of large investors have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Delcath Systems in the third quarter worth $102,000. Riverwater Partners LLC acquired a new position in Delcath Systems during the 3rd quarter worth $161,000. Levin Capital Strategies L.P. lifted its position in Delcath Systems by 12.2% during the 1st quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock worth $262,000 after acquiring an additional 5,969 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Delcath Systems in the second quarter valued at about $370,000. Finally, Renaissance Technologies LLC bought a new position in shares of Delcath Systems in the second quarter worth about $694,000. Institutional investors own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.